Jiangxi Kvvit Pharmaceutical

Jiangxi Kvvit Pharmaceutical Co., Ltd. is a leading innovation-driven pharmaceutical company and a wholly-owned subsidiary of the Qingfeng Pharmaceutical Group. Established in December 2021 to consolidate the group's chemical drug business, Kvvit focuses on the research, development, and commercialization of differentiated medicines in four key therapeutic areas: anti-infectives, oncology, the digestive system, and the central nervous system. The company's portfolio includes the innovative influenza polymerase acidic (PA) inhibitor suraxavir marboxil (GP681), which was approved in China in 2025, and eribulin mesylate, a microtubule inhibitor marketed in partnership with Hikma Pharmaceuticals. Kvvit operates state-of-the-art manufacturing facilities in Ganzhou that meet US FDA and EU EMA standards, supporting a robust pipeline of over 60 programs at various stages of development.